Nasal boosters will be essential to thwart future Covid variants: Study

Widely available vaccinations may not be enough to stop the spread of Covid virus and the future variants. But, using nasal spray as boosters may help in the longer run

Coronavirus vaccines, booster shot
Photo: Bloomberg
IANS New York
3 min read Last Updated : Jul 20 2022 | 4:04 PM IST

Widely available vaccinations may not be enough to stop the spread of Covid virus and the future variants. But, using nasal spray as boosters may help keep the majority of the population free from serious illness from the disease, suggests research.

Published Tuesday in the journal Science Immunology, the research fully documents for the first time the underperforming immune response in the airways of people with Covid-19 vaccinations compared to those with natural infection.

"Our data suggest that an intranasal vaccine-boosting strategy will be critical to protect people against emerging variants of concern," said Jie Sun, Professor of Medicine at University of Virginia.

Bloodstreams get strongly ramped up by the mRNA vaccine, while the mucosal linings experience moderate or little neutralising antibody response, the study found.

"The Omicron variant almost completely escaped neutralisation by mucosal antibodies in individuals who received mRNA vaccines and in previously infected individuals," said Sun.

"Our data showed that mRNA vaccination also did not induce sufficient tissue-residing cellular immunity in the airways, another arm of our immune system to prevent the entry of the virus into our bodies."

Only the bodies of unvaccinated patients who were seriously ill put up a vigorous fight against the virus in both their airways and their bloodstreams, the researchers found -- a less-than-ideal way of achieving a united front.

On the contrary, mice that were administered a nasally delivered vaccine originating from adenovirus -- a relative in the family of cold viruses that expresses the spike protein found in Covid -- demonstrated "robust neutralising antibody responses" in combination with mRNA vaccine shots.

"The nasal vaccine provides a mucosal antigen boost to the pre-existing memory of T and B cells that direct immune response, resulting in higher cellular and humoral immunity," Sun explained.

The uptick was found not only in the bronchi of the lungs, but also as an improvement over the bloodstream's normal vaccinated response.

And the response was "effective against the ancestral virus as well as the Omicron variant," he said.

The research further validates scientists' suspicion that greater immunity to the coronavirus can be developed starting where the virus first takes root, the mucus membranes of the nose -- perhaps stopping it cold.

In humans, Sun said, "We think the robust antibody responses in the respiratory tract would neutralise the virus immediately upon viral entry when the individual contracts the virus, preventing the establishment of viral infection and subsequent passing of the infection to others."

--IANS

rvt/dpb

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jul 20 2022 | 4:04 PM IST

Next Story